TABLE 2:
Bacteriological cure rate by treatment strategy, time of examination and evaluation criteria by EMEA and DVG
| Day of examination and bacteriological status at day 0 | Treatment strategy | |||||||||||
| Individualised homeopathy (n = 60) | Placebo (n = 60) | Antibiotic (n = 60) | ||||||||||
| EMEA* | DVG * | EMEA | DVG | EMEA | DVG | |||||||
| n/n | % | n/n | % | n/n | % | n/n | % | n/n | % | n/n | % | |
| Day 7 | ||||||||||||
| Positive (n=120) | ||||||||||||
| BacC | 17/40 | 42.5 | 10/40 | 25.0 | 17/38 | 44.7 | 12/38 | 31.6 | 34/42 | 81.0 | 30/42 | 71.4 |
| NoBacC | 8/40 | 20.0 | 8/40 | 20.0 | 4/38 | 10.5 | 4/38 | 10.5 | 5/42 | 11.9 | 5/42 | 11.9 |
| NewInf | – | – | 7/40 | 17.5 | – | – | 5/38 | 13.2 | – | – | 4/42 | 9.5 |
| Non-responders | 15/40 | 37.5 | 15/40 | 37.5 | 17/38 | 44.7 | 17/38 | 44.7 | 3/42 | 7.1 | 3/42 | 7.1 |
| Negative (n=60) | ||||||||||||
| BacC | 19/20 | 95.0 | 12/20 | 60.0 | 22/22 | 100.0 | 17/22 | 77.3 | 18/18 | 100.0 | 13/18 | 72.2 |
| NewInf | – | – | 7/20 | 35.0 | – | – | 5/22 | 22.7 | – | – | 5/18 | 27.8 |
| Non-responders | 1/20 | 5.0 | 1/20 | 5.0 | 0/22 | 0.0 | 0/22 | 0.0 | 0/18 | 0.0 | 0/18 | 0.0 |
| Day 14 | ||||||||||||
| Positive (n=120) | ||||||||||||
| BacC | 14/40 | 35.0 | 12/40 | 30.0 | 18/38 | 47.4 | 13/38 | 34.2 | 28/42 | 66.7 | 23/42 | 54.8 |
| NoBacC | 5/40 | 12.5 | 5/40 | 12.5 | 0/38 | 0.0 | 0/38 | 0.0 | 4/42 | 9.4 | 4/42 | 9.4 |
| NewInf | – | – | 2/40 | 5.0 | – | – | 5/38 | 13.2 | – | – | 5/42 | 11.9 |
| Non-responders | 21/40 | 52.5 | 21/40 | 52.5 | 20/38 | 52.6 | 20/38 | 52.6 | 10/42 | 23.8 | 10/42 | 23.8 |
| Negative (n=60) | ||||||||||||
| BacC | 17/20 | 85.0 | 13/20 | 65.0 | 18/22 | 81.8 | 11/22 | 50.0 | 16/18 | 88.9 | 13/18 | 72.2 |
| NewInf | – | – | 4/20 | 20.0 | – | – | 7/22 | 31.8 | – | – | 3/18 | 16.7 |
| Non-responders | 3/20 | 15.0 | 3/20 | 15.0 | 4/22 | 18.2 | 4/22 | 18.2 | 2/18 | 11.1 | 2/18 | 11.1 |
| Day 28 | ||||||||||||
| Positive (n=120) | ||||||||||||
| BacC | 13/39† | 33.3 | 9/39 | 23.1 | 17/38 | 44.7 | 13/38 | 34.2 | 25/42 | 59.5 | 23/42 | 54.8 |
| NoBacC | 2/39 | 5.1 | 2/39 | 5.1 | 0/38 | 0.0 | 0/38 | 0.0 | 2/42 | 4.8 | 2/42 | 4.8 |
| NewInf | – | – | 4/39 | 10.2 | – | – | 4/38 | 10.5 | – | – | 2/42 | 4.8 |
| Non-responders | 24/39 | 61.5 | 24/39 | 61.5 | 21/38 | 55.3 | 21/38 | 55.3 | 15/42 | 35.7 | 15/42 | 35.7 |
| Negative (n=60) | ||||||||||||
| BacC | 15/19† | 78.9 | 13/19 | 68.4 | 16/22 | 72.7 | 14/22 | 63.6 | 13/17† | 76.5 | 10/17 | 58.8 |
| NewInf | – | – | 2/19 | 10.5 | – | – | 2/22 | 9.1 | – | – | 3/17 | 17.6 |
| Non-responders | 4/19 | 21.1 | 4/19 | 21.1 | 6/22 | 27.3 | 6/22 | 27.3 | 4/17 | 23.5 | 4/17 | 23.5 |
Results are given in number of total cures out of cases treated (n/n) and in % of all cases treated.
*Evaluation criteria according to EMEA or DVG.
†Early culling of one cow due to different reasons (dangerous handling, lameness, fertility disorder).
BacC, bacteriological cure (elimination of the pathogen present on day 0); DVG, German Veterinary Association; EMEA, European Agency for the Evaluation of Medicinal Products; NewInf, newly infected udder quarter (pathogen was different from the one on day 0); NoBacC, no bacteriological cure (the pathogen on day 0 was still present in the udder); non-responders, cows with no clinical cure were rated as non-responsive to the treatment given.